Previous 10 | Next 10 |
Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, announced today that members of its executive leadership team will participate at two upcoming investor conferences. On Octob...
The Agreement Substantially Increases Procaps' Participation in the Oncology Market in the LatAm Region Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, announced today...
2023-09-05 13:19:05 ET Procaps Group S.A. (PROC) Q2 2023 Earnings Call Transcript September 5, 2023, 11:00 AM ET Company Participants Melissa Angelini - IR Director Ruben Minski - CEO Patricio Vargas - CFO Conference Call Participants Kemp Doliver - B...
Net Revenues Increased 7% in 1H23 Year-over-Year, on a Constant Currency Basis, Signaling Positive Performance of Rx Products Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated international healthcare and pharmaceutical ser...
AeroVironment Inc. (AVAV) is expected to report $0.4 for Q1 2024 Jeronimo Martins - S.G.P.S., S.A. ADR (JRONY) is expected to report $0.74 for Q2 2023 TuSimple Holdings Inc. (TSP) is expected to report $-0.63 for Q2 2023 CVR Medical Corp (CRRVF) is expected to report for quarter end 2...
Procaps Group S.A. (PROC) is expected to report $0.06 for Q2 2023
Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, announced that it will report its results for the second quarter and six months ended June 30, 2023, before market opens on Tuesday, September 5, 2023. The Compan...
Introduces New High Temperature Gummy Technology Platform that Solves Formulation and Distribution Challenges Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, announced...
2023-06-06 01:14:16 ET Procaps Group press release ( NASDAQ: PROC ): Q1 Revenue of $84M beats by $1M . On a constant currency basis, net revenues increased by 10%. Gross profit for 1Q23 totaled $46 million, with a 55% gross margin. Adjusted EBITDA reached $9 m...
MIAMI and BARRANQUILLA, Colombia, June 05, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps”), a leading integrated international healthcare and pharmaceutical services company, today announced its 1Q23 financial results. “We are executing on our ...
News, Short Squeeze, Breakout and More Instantly...
Procaps Group S.A. Company Name:
PROC Stock Symbol:
NASDAQ Market:
Procaps Group (Nasdaq: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it has received a letter from the Nasdaq Stock Market, dated May 16, 2024 (the “Delinquency Letter”)...
Procaps Group (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it has determined it is unable to file its Annual Report on Form 20-F for the fiscal year ended December 31, 2023,...
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's futu...